Latest News

Show Your Support of HR 3772

Access to important diagnostic procedure is at risk
Antique red and white Megaphone. (vintage style)
A change in 2020 to medicare reimbursement of Gallium-68 PET/CT may reduce access to this diagnostic unless we act

On October 18, 2019, an opinion piece that NorCal CarciNET Community’s Josh Mailman opinion article (“CMS policy shouldn’t penalize those with rare disease”) was published by The Hill,  The opinion piece highlighted the challenges with the current method that Medicare/CMS use to pay for radiopharmaceuticals. This webpage provides more information on how this will impact NET patients and providers along with a  tool for those that are interested in taking action.

The Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2019 (H.R. 3772)